You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 10/13/2015

Company Name Symbol %Change
Amgen: 52-Week High Recently Eclipsed (AMGN)

Print Share

Dec 11, 2012 (52 Week high-lows via COMTEX) -- Shares of Amgen (NASDAQ:AMGN) traded at a new 52-week high today of $90.25. So far today approximately 2.9 million shares have been exchanged, as compared to an average 30-day volume of 4.5 million shares.

Amgen share prices have moved between a 52-week high of $90.25 and a 52-week low of $57.14 and are now trading 57% above that low price at $89.74 per share. The 200-day and 50-day moving averages have moved 0.38% higher and 0.27% higher over the past week, respectively.

Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.

Potential upside of 5.0% exists for Amgen, based on a current level of $89.74 and analysts' average consensus price target of $94.19. The stock should find initial support at its 50-day moving average (MA) of $85.58 and further support at its 200-day MA of $76.19.


Financial News Network Online (FNNO) is a leading provider of digital financial news content for distribution on the web. You can count on FNNO to bring you the latest market news, earnings reports, analyst comments, economic data reports and more. Visit today.

Copyright, Comtex News Network, Inc. 2012

Free Stock Analysis From Zacks

Includes Zacks Long-Term Recommendation and Target Price

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.